Emoxypine succinate (Mexidol)

Overview

Emoxypine succinate (Mexidol) is a non-peptide small-molecule 3-hydroxypyridine derivative, the succinate salt of 2-ethyl-6-methyl-3-hydroxypyridine. It is a registered prescription drug in Russia and CIS states since the 1990s (IV/IM solution and oral tablet forms) but is NOT approved by the FDA or EMA. In the US and EU, it is sold only as an unregulated research chemical by nootropic vendors, typically labeled "not for human consumption." A 2024 peer-reviewed analysis flags its antihypoxic/metabolic-modulator profile as pharmacologically similar to WADA-banned agents meldonium and trimetazidine, documents past use by Russian athletes, and identifies it as a candidate for future prohibited-list consideration—though it is not currently WADA-prohibited.

Mechanism of Action

Proposed antioxidant and membrane-protective mechanism (per narrative review): scavenges lipophilic and water-soluble free radicals in phospholipid membranes, upregulates catalase and glutathione peroxidase, decreases membrane microviscosity, and allosterically modulates membrane-bound receptors including enhanced GABA-benzodiazepine receptor complex binding. The succinate moiety is proposed to act as an oxidizable substrate for succinate dehydrogenase (mitochondrial complex II), supporting ATP synthesis under hypoxic/ischemic stress. In vitro work shows the compound is not a substrate of but does inhibit ABCB1 (P-glycoprotein) and SLCO1B1 (OATP1B1) drug transporters. This molecular mechanistic picture derives largely from a single narrative review plus one in-vitro transporter study and has not been independently replicated at the molecular level in Western literature.

Research Summary

Human data: Registered/marketed prescription drug in Russia and CIS states since the 1990s; multiple Russia-conducted trials exist, including a published multicenter double-blind placebo-controlled RCT (MEGA) in 333 children aged 6–12 with ADHD across 14 Russian centers using 125 mg tablets. No FDA/EMA-reviewed pivotal trial or US-marketed product exists; independent non-Russian-sponsored replication is limited. Preclinical: In rats (180–240 g), 6.25–25 mg/kg emoxypine reduced forced-swim-test immobility by ~24% and orientational activity by ~53% (antidepressant-like activity, animal data only). In isolated/anesthetized rat hearts, 10 mg/kg IV increased collateral coronary blood flow without altering systemic blood pressure (animal data only). In vitro (Caco-2/HEK293-SLCO1B1/HepG2 cell lines), the compound inhibited ABCB1 and SLCO1B1 transporters less potently than reference inhibitors; authors judged systemic effect not clinically significant.

Reported Side Effects

• Not FDA- or EMA-approved; sold in US/EU only as unregulated research chemical
• Theoretical drug-interaction risk via ABCB1/P-glycoprotein and SLCO1B1/OATP1B1 inhibition
• Pharmacologically similar to WADA-banned metabolic modulators (meldonium, trimetazidine); flagged for future prohibited-list consideration
• No FDA/EMA safety review for gray-market powder; purity/identity not independently verified
• Past use documented by Russian athletes (2024 peer-reviewed analysis)

Compare Emoxypine succinate (Mexidol) with Others

Research References

• Emoxypine succinate | C12H17NO5 | CID 122298 (PubChem).
• NCATS Inxight Drugs — EMOXYPINE SUCCINATE (CAS 127464-43-1, UNII 2R985002CT).
• Promising effects of emoxypine and its succinate derivative in the management of various diseases (narrative review). 2022.
• Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1. 2023. PMID 38004395.

Frequently asked questions

Has Emoxypine succinate (Mexidol) been independently lab-tested?

Disclosed Labs has collected 1 Certificate of Analysis (COA) for Emoxypine succinate (Mexidol) from 1 independent testing lab. 1 vendor has submitted material for testing. Products average 99.9% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/emoxypine-succinate/testing.

How does Emoxypine succinate (Mexidol) work?

Proposed antioxidant and membrane-protective mechanism (per narrative review): scavenges lipophilic and water-soluble free radicals in phospholipid membranes, upregulates catalase and glutathione peroxidase, decreases membrane microviscosity, and allosterically modulates membrane-bound receptors including enhanced GABA-benzodiazepine receptor complex binding. The succinate moiety is proposed to act as an oxidizable substrate for succinate dehydrogenase (mitochondrial complex II), supporting ATP synthesis under hypoxic/ischemic stress. In vitro work shows the compound is not a substrate of but does inhibit ABCB1 (P-glycoprotein) and SLCO1B1 (OATP1B1) drug transporters. This molecular mechanistic picture derives largely from a single narrative review plus one in-vitro transporter study and has not been independently replicated at the molecular level in Western literature.

What does the research say about Emoxypine succinate (Mexidol)?

Human data: Registered/marketed prescription drug in Russia and CIS states since the 1990s; multiple Russia-conducted trials exist, including a published multicenter double-blind placebo-controlled RCT (MEGA) in 333 children aged 6–12 with ADHD across 14 Russian centers using 125 mg tablets. No FDA/EMA-reviewed pivotal trial or US-marketed product exists; independent non-Russian-sponsored replication is limited. Preclinical: In rats (180–240 g), 6.25–25 mg/kg emoxypine reduced forced-swim-test immobility by ~24% and orientational activity by ~53% (antidepressant-like activity, animal data only). In isolated/anesthetized rat hearts, 10 mg/kg IV increased collateral coronary blood flow without altering systemic blood pressure (animal data only). In vitro (Caco-2/HEK293-SLCO1B1/HepG2 cell lines), the compound inhibited ABCB1 and SLCO1B1 transporters less potently than reference inhibitors; authors judged systemic effect not clinically significant.